Literature DB >> 19080177

Microinflammation is involved in the dysfunction of arteriovenous fistula in patients with maintenance hemodialysis.

Bi-cheng Liu1, Li Li, Min Gao, Yan-li Wang, Ji-rong Yu.   

Abstract

BACKGROUND: Vascular access (VA) dysfunction is a major clinical complication in the hemodialysis population and has a direct effect on dialysis outcome. This study was conducted to explore the role of microinflammation in the VA dysfunction in maintenance hemodialysis patients.
METHODS: Forty-seven patients (male 35 and female 12) receiving maintenance hemodialysis were included for this study. They were divided into three groups: group 1 (n = 15), patients with initial hemodialysis and new arteriovenous fistula (AVF); group 2 (n = 18), patients treated with hemodialysis for long term with well-functional VA; group 3 (n = 14), maintenance hemodialysis patients with VA dysfunction. Biochemical parameters and serum tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) were determined. High-sensitivity C-reactive protein (hs-CRP) was determined by latex-enhanced immuno-nephelometric method. Tissues of radial artery were taken from group 1 and group 3 for the histological study. Expression of CD68 and MCP-1 in the radial artery was determined by immunohistochemistry.
RESULTS: Serum hs-CRP in group 3 was significantly higher than those in group 1 and group 2 ((7.40 +/- 2.42) mg/L vs (4.21 +/- 1.62) mg/L and (5.04 +/- 3.65) mg/L, P < 0.01 and P < 0.05, respectively). Serum TNF-alpha in group 3 was significantly higher than those in group 1 and group 2 ((64.03 +/- 9.29) pg/ml vs (54.69 +/- 12.39) pg/ml and (54.05 +/- 7.68) pg/ml, P < 0.05 and P < 0.01, respectively). Serum IL-6 in group 3 was also significantly higher than those in group 1 and group 2 ((70.09 +/- 14.53) pg/ml vs (56.43 +/- 10.11) pg/ml and (60.77 +/- 9.70) pg/ml, P < 0.01 and P < 0.05, respectively). Patients in group 3 had a thicker internal layer of vessels than in group 1 ((0.356 +/- 0.056) mm vs (0.111 +/- 0.021) mm, P < 0.01). Expression of CD68 and MCP-1 in the fistula vessel walls in group 3 were much higher than those in group 1 (P < 0.01). Moreover, serum hs-CRP level was positively correlated with the neointimal hyperplasia, the expression of CD68 and MCP-1 in fistula vessel (P < 0.01, respectively).
CONCLUSION: Microinflammation might be involved in the dysfunction of AVF in patients with maintenance hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19080177

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  12 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Adipose phenotype predicts early human autogenous arteriovenous hemodialysis remodeling.

Authors:  Christine R Mauro; Kui Ding; Hui Xue; Ming Tao; Alban Longchamp; Michael Belkin; Bruce S Kristal; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2014-09-26       Impact factor: 4.268

3.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

4.  CD44 Promotes Inflammation and Extracellular Matrix Production During Arteriovenous Fistula Maturation.

Authors:  Go Kuwahara; Takuya Hashimoto; Masayuki Tsuneki; Kota Yamamoto; Roland Assi; Trenton R Foster; Jesse J Hanisch; Hualong Bai; Haidi Hu; Clinton D Protack; Michael R Hall; John S Schardt; Steven M Jay; Joseph A Madri; Shohta Kodama; Alan Dardik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-04-27       Impact factor: 8.311

5.  Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula.

Authors:  Maheshika Somarathna; Patrick Tj Hwang; Reid C Millican; Grant C Alexander; Tatyana Isayeva-Waldrop; Jennifer A Sherwood; Brigitta C Brott; Isabelle Falzon; Hannah Northrup; Yan-Ting Shiu; Chris J Stubben; John Totenhagen; Ho-Wook Jun; Timmy Lee
Journal:  Biomaterials       Date:  2021-11-18       Impact factor: 15.304

Review 6.  Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.

Authors:  Timmy Lee; Prabir Roy-Chaudhury
Journal:  Adv Chronic Kidney Dis       Date:  2009-09       Impact factor: 3.620

7.  Sclerostin as a new key player in arteriovenous fistula calcification.

Authors:  M Balcı; A Kırkpantur; A Turkvatan; S Mandıroglu; E Ozturk; B Afsar
Journal:  Herz       Date:  2013-10-19       Impact factor: 1.443

8.  Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula.

Authors:  Binxia Yang; Akshaar Brahmbhatt; Evelyn Nieves Torres; Brian Thielen; Deborah L McCall; Sean Engel; Aditya Bansal; Mukesh K Pandey; Allan B Dietz; Edward B Leof; Timothy R DeGrado; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  Radiology       Date:  2015-11-19       Impact factor: 11.105

9.  Interleukin-6 -634 C/G and -174 G/C polymorphisms in Korean patients undergoing hemodialysis.

Authors:  Jung-Hwa Ryu; Seung-Jung Kim
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

10.  Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis.

Authors:  Danyelle Romana Alves Rios; Melina Barros Pinheiro; Wander Valadares de Oliveira Junior; Karina Braga Gomes; Andréa Teixeira Carvalho; Olindo Assis Martins-Filho; Ana Cristina Simões E Silva; Luci Maria Sant'Ana Dusse
Journal:  Dis Markers       Date:  2017-07-27       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.